- Press Releases
- Events & Presentations
- Corporate Governance
- Shareholder & Stock Info
- Financial Reports
- Financial calendar
The members of the nomination committee shall, irrespective of how they are appointed, attend to the interests of all shareholders. The annual general meeting resolves how the nomination shall be appointed.
Nomination Committee of the Annual General Meeting 2017
In accordance with the principles of appointing the nomination committee, adopted by the annual general meeting of 26 October 2016, the chairman of the board of directors has contacted the major shareholders in order to appoint a nomination committee. The nomination committee of Immunicum consist of the four members appointed by the four largest shareholders that have accepted the invitation to participate in the election committee.
The nomination committee before the annual general meeting of 2017 is convened by the chairman of Immunicum’s board of directors Agneta Edberg and consists of Evert Carlsson (chairman of the nomination committee, appointed by Swedbank Robur Fonder), Martin Lindström (appointed by Loggen Invest AB), Bengt Andersson (appointed by Bengt Andersson) and Mats Dahlgren (appointed by Mats Dahlgren). The nomination committee’s assignment is to prepare the following proposals to the annual general meeting of 2017: (i) proposal of election of the chairman of the annual general meeting; (ii) proposal of election of board members; (iii) proposal of election of the chairman of the board of directors; (iv) proposal of the remuneration to the board of directors; (v) proposal of election of auditors (if instructed pursuant to Chapter 8 Section 49 b Paragraph 2 of the Companies Act); (vi) proposal of remuneration to the auditors; and (vii) proposal of principles of the nomination committee before the annual general meeting of 2018.
The annual general meeting in Immunicum will held on 26 April 2017.
Shareholders who wish to leave proposal to the nomination committee can do so by email to email@example.com or by letter to Immunicum AB (publ), Att: Valberedningen, Grafiska vägen 2, 412 63 Göteborg.